the mission of infinity pharmaceuticals, inc. is to discover, develop, and deliver to patients best-in-class medicines for the treatment of difficult-to-treat diseases, with a strong focus in oncology and inflammation. small molecule discovery and development capabilities infinity’s programs arise from the integration of a broad range of research and development capabilities, including strengths in cancer biology, medicinal chemistry, clinical and translational medicine, and drug product process development and formulation. strategic alliances building on its strengths in innovative small molecule drug discovery and development, infinity has established significant alliances with leading pharmaceutical and biotechnology companies to help realize the full potential of its product pipeline. business and scientific expertise the company has assembled a team of passionate, committed, and innovative individuals who bring together their collective expertise in all areas of business
Company profile
Ticker
INFIQ, INFIQ
Exchange
Website
CEO
Adelene Perkins
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
DISCOVERY PARTNERS INTERNATIONAL INC
SEC CIK
Corporate docs
Subsidiaries
Infinity Discovery, Inc. • Infinity Security Corporation ...
IRS number
330655706
INFIQ stock data
Latest filings (excl ownership)
25-NSE
Exchange delisting
20 Nov 23
8-K
Bankruptcy or Receivership
29 Sep 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
13 Sep 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
11 Sep 23
8-K
Cost Associated with Exit or Disposal Activities
1 Sep 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
8-K
Infinity Pharmaceuticals Announces Value Preservation and Maximization Plan
25 Jul 23
8-K
Infinity Pharmaceuticals Announces Termination of Merger Agreement with MEI Pharma
24 Jul 23
8-K
Submission of Matters to a Vote of Security Holders
14 Jul 23
DEFA14A
Additional proxy soliciting materials
10 Jul 23
Transcripts
INFIQ
Earnings call transcript
2022 Q3
14 Nov 22
INFIQ
Earnings call transcript
2022 Q2
10 Aug 22
INFIQ
Earnings call transcript
2022 Q1
4 May 22
INFIQ
Earnings call transcript
2021 Q4
30 Mar 22
INFIQ
Earnings call transcript
2021 Q3
3 Nov 21
INFIQ
Earnings call transcript
2021 Q1
14 May 21
INFIQ
Earnings call transcript
2020 Q4
17 Mar 21
INFIQ
Earnings call transcript
2020 Q3
9 Nov 20
INFIQ
Earnings call transcript
2020 Q2
31 Jul 20
INFIQ
Earnings call transcript
2020 Q1
12 May 20
Latest ownership filings
4
Adelene Q Perkins
12 Sep 23
SC 13G/A
Polar Capital Holdings Plc
14 Feb 23
SC 13G/A
VANGUARD GROUP INC
9 Feb 23
4
Stephane Peluso
4 Aug 22
SC 13G
BlackRock Inc.
8 Jul 22
4
ANTHONY B EVNIN
16 Jun 22
4
DAVID W BEIER
16 Jun 22
4
RICHARD GAYNOR
16 Jun 22
4
Samuel Agresta
16 Jun 22
4
NORMAN C SELBY
16 Jun 22
Financial summary
Quarter (USD) | Jun 23 | Mar 23 | Dec 22 | Sep 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 17.90 mm | 17.90 mm | 17.90 mm | 17.90 mm | 17.90 mm | 17.90 mm |
Cash burn (monthly) | 2.66 mm | 2.34 mm | 3.37 mm | 3.50 mm | 2.67 mm | 3.24 mm |
Cash used (since last report) | 23.83 mm | 20.95 mm | 30.18 mm | 31.35 mm | 23.88 mm | 28.99 mm |
Cash remaining | -5.93 mm | -3.04 mm | -12.28 mm | -13.45 mm | -5.98 mm | -11.09 mm |
Runway (months of cash) | -2.2 | -1.3 | -3.6 | -3.8 | -2.2 | -3.4 |
Institutional ownership, Q2 2023
30.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 48 |
Opened positions | 3 |
Closed positions | 9 |
Increased positions | 8 |
Reduced positions | 14 |
13F shares | Current |
---|---|
Total value | 4.10 bn |
Total shares | 27.19 mm |
Total puts | 20.10 k |
Total calls | 74.90 k |
Total put/call ratio | 0.3 |
Largest owners | Shares | Value |
---|---|---|
Biotechnology Value Fund L P | 6.35 mm | $0.00 |
BVF | 6.35 mm | $1.34 bn |
Vanguard | 3.98 mm | $838.18 mm |
Sphera Funds Management | 1.48 mm | $310.70 mm |
BLK Blackrock | 1.46 mm | $307.73 mm |
Carlson Capital L P | 1.30 mm | $273.65 mm |
Mariner | 1.20 mm | $252.00 mm |
Geode Capital Management | 807.52 k | $169.98 mm |
Integrated Core Strategies | 743.27 k | $1.67 mm |
Ergoteles | 696.51 k | $146.62 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
12 Sep 23 | Adelene Q Perkins | Common Stock | Sell | Dispose S | No | Yes | 0.07 | 410,196 | 28.71 k | 1,175,291 |
9 Sep 23 | Adelene Q Perkins | Common Stock | Option exercise | Acquire M | No | No | 0 | 768,133 | 0.00 | 1,585,487 |
9 Sep 23 | Adelene Q Perkins | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 768,133 | 0.00 | 0 |